{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:16:13Z","timestamp":1790363773108,"version":"4.1.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Respiratory syncytial virus (RSV) is a leading cause of hospitalization and infant mortality worldwide. There are currently no approved vaccines against RSV, and immunoprophylaxis with the mAb palivizumab is limited to extremely vulnerable infants in resource-rich settings due to its high cost and the need for monthly injections throughout the RSV season. Nirsevimab (formerly MEDI8897) is a highly potent, long-acting, human, recombinant mAb that received approval for the prevention of RSV infection in newborns and infants during their first RSV season from the EMA and the UK\u2019s Medicines and Healthcare products Regulatory Agency in November 2022 based on positive results in Phase 2b and 3 clinical trials. Nirsevimab targets the highly conserved site \u00d8 of the prefusion conformation of the RSV fusion (F) protein and contains a triple amino acid substitution in the Fc domain that extends its half-life, allowing for a single dose to cover a typical RSV season in regions with temperate climates. In this article I review key attributes of nirsevimab with an emphasis on pharmacology, pharmacokinetics, antiviral activity, and the potential for resistance and escape variants. I also summarize current progress in clinical trials and consider future research priorities.<\/jats:p>","DOI":"10.1093\/jac\/dkad076","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T04:06:24Z","timestamp":1678939584000},"page":"1143-1149","source":"Crossref","is-referenced-by-count":46,"title":["Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1333-0378","authenticated-orcid":false,"given":"Sarah C J","family":"Jorgensen","sequence":"first","affiliation":[{"name":"Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto , 1 King\u2019s College Circle, Toronto M5S 1A8, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"2023050300194358900_dkad076-B1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"2023050300194358900_dkad076-B2","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1016\/S2214-109X(19)30264-5","article-title":"Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis","volume":"7","author":"Li","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"Suppl 3","key":"2023050300194358900_dkad076-B3","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1093\/infdis\/jit515","article-title":"Respiratory syncytial virus circulation in seven countries with global disease detection regional centers","volume":"208","author":"Haynes","year":"2013","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B5","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"2023050300194358900_dkad076-B6","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee","year":"2014","journal-title":"Pediatrics"},{"key":"2023050300194358900_dkad076-B7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"key":"2023050300194358900_dkad076-B8","author":"World Health Organization"},{"key":"2023050300194358900_dkad076-B9","author":"PATH"},{"key":"2023050300194358900_dkad076-B10","author":"European Medicines Agency"},{"key":"2023050300194358900_dkad076-B11","author":"Medicines and Healthcare products Regulatory Agency (MHRA)"},{"key":"2023050300194358900_dkad076-B12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"2023050300194358900_dkad076-B13","first-page":"20143085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc Biol Sci"},{"key":"2023050300194358900_dkad076-B14","doi-asserted-by":"crossref","first-page":"2515135520981516","DOI":"10.1177\/2515135520981516","article-title":"Strategies for active and passive pediatric RSV immunization","volume":"9","author":"Eichinger","year":"2021","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"Suppl 1","key":"2023050300194358900_dkad076-B15","doi-asserted-by":"crossref","first-page":"i102","DOI":"10.1093\/ije\/dyq027","article-title":"Tetanus toxoid immunization to reduce mortality from neonatal tetanus","volume":"39","author":"Blencowe","year":"2010","journal-title":"Int J Epidemiol"},{"key":"2023050300194358900_dkad076-B16","doi-asserted-by":"crossref","first-page":"e70867","DOI":"10.1371\/journal.pone.0070867","article-title":"IgA and neutralizing antibodies to influenza A virus in human milk: a randomized trial of antenatal influenza immunization","volume":"8","author":"Schlaudecker","year":"2013","journal-title":"PLoS One"},{"key":"2023050300194358900_dkad076-B17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40121-019-00264-7","article-title":"Immunological and clinical benefits of maternal immunization against pertussis: a systematic review","volume":"8","author":"Switzer","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2023050300194358900_dkad076-B18","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.vaccine.2022.06.034","article-title":"Biological factors that may impair transplacental transfer of RSV antibodies: implications for maternal immunization policy and research priorities for low- and middle-income countries","volume":"40","author":"Atwell","year":"2022","journal-title":"Vaccine"},{"key":"2023050300194358900_dkad076-B19","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Simoes","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023050300194358900_dkad076-B20","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2023050300194358900_dkad076-B21","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV virus taxonomy profile: Pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J Gen Virol"},{"key":"2023050300194358900_dkad076-B22","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"2023050300194358900_dkad076-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.13.1.1","article-title":"Respiratory syncytial virus genetic and antigenic diversity","volume":"13","author":"Sullender","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"2023050300194358900_dkad076-B24","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"2023050300194358900_dkad076-B25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","article-title":"Immunological lessons from respiratory syncytial virus vaccine development","volume":"51","author":"Ruckwardt","year":"2019","journal-title":"Immunity"},{"key":"2023050300194358900_dkad076-B26","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jix489","article-title":"Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection","volume":"216","author":"Capella","year":"2017","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B27","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"2023050300194358900_dkad076-B28","doi-asserted-by":"crossref","first-page":"e1006837","DOI":"10.1371\/journal.ppat.1006837","article-title":"Human antibody recognition of antigenic site IV on pneumovirus fusion proteins","volume":"14","author":"Mousa","year":"2018","journal-title":"PLoS Pathog"},{"key":"2023050300194358900_dkad076-B29","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9: eaaj1928","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023050300194358900_dkad076-B30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biologicals.2009.02.017","article-title":"The cotton rat model of respiratory viral infections","volume":"37","author":"Boukhvalova","year":"2009","journal-title":"Biologicals"},{"key":"2023050300194358900_dkad076-B31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B32","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1038\/s41598-019-40387-y","article-title":"Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17","volume":"9","author":"Bin","year":"2019","journal-title":"Sci Rep"},{"key":"2023050300194358900_dkad076-B33","doi-asserted-by":"crossref","first-page":"e0175792","DOI":"10.1371\/journal.pone.0175792","article-title":"Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV\/A and RSV\/B","volume":"12","author":"Hause","year":"2017","journal-title":"PLoS One"},{"key":"2023050300194358900_dkad076-B34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jir790","article-title":"Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab","volume":"205","author":"Zhu","year":"2012","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcv.2015.01.016","article-title":"Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis","volume":"65","author":"Oliveira","year":"2015","journal-title":"J Clin Virol"},{"key":"2023050300194358900_dkad076-B36","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B37","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1038\/s41598-018-22826-4","article-title":"Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"2023050300194358900_dkad076-B38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiy189","article-title":"Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897","volume":"218","author":"Zhu","year":"2018","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"2023050300194358900_dkad076-B40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"2023050300194358900_dkad076-B41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"386","author":"Domachowske","year":"2022","journal-title":"N Engl J Med"},{"key":"2023050300194358900_dkad076-B42","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2023050300194358900_dkad076-B43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Simoes","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2023050300194358900_dkad076-B44","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","article-title":"Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children","volume":"56","author":"Robbie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300194358900_dkad076-B45"},{"key":"2023050300194358900_dkad076-B46"},{"key":"2023050300194358900_dkad076-B47"},{"key":"2023050300194358900_dkad076-B48"},{"key":"2023050300194358900_dkad076-B49"},{"key":"2023050300194358900_dkad076-B50","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1542\/peds.2008-1036","article-title":"Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial","volume":"125","author":"Carbonell-Estrany","year":"2010","journal-title":"Pediatrics"},{"key":"2023050300194358900_dkad076-B51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","article-title":"A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease","volume":"70","author":"Feltes","year":"2011","journal-title":"Pediatr Res"},{"key":"2023050300194358900_dkad076-B52","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J"},{"key":"2023050300194358900_dkad076-B53","doi-asserted-by":"crossref","first-page":"e046563","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model","volume":"11","author":"Baral","year":"2021","journal-title":"BMJ Open"},{"key":"2023050300194358900_dkad076-B54","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1016\/j.vaccine.2022.10.041","article-title":"Optimal respiratory syncytial virus intervention programmes using nirsevimab in England and Wales","volume":"40","author":"Hodgson","year":"2022","journal-title":"Vaccine"},{"key":"2023050300194358900_dkad076-B55","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","article-title":"Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model","volume":"226","author":"Kieffer","year":"2022","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-021-00566-9","article-title":"Potential impact of nirsevimab on RSV transmission and medically attended lower respiratory tract illness caused by RSV: a disease transmission model","volume":"11","author":"Voirin","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"Suppl 2","key":"2023050300194358900_dkad076-B57","first-page":"S282","article-title":"Accurately assessing the expected impact of universal first RSV season immunization with nirsevimab against RSV-related outcomes and costs among all US infants","volume":"226","author":"Fullarton","year":"2022","journal-title":"J Infect Dis"},{"key":"2023050300194358900_dkad076-B58","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/irv.12771","article-title":"Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17","volume":"14","author":"Jackson","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"2023050300194358900_dkad076-B59","doi-asserted-by":"crossref","first-page":"e0200319","DOI":"10.1371\/journal.pone.0200319","article-title":"Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States","volume":"13","author":"Ruzin","year":"2018","journal-title":"PLoS One"},{"key":"2023050300194358900_dkad076-B60","doi-asserted-by":"crossref","first-page":"ofab159","DOI":"10.1093\/ofid\/ofab159","article-title":"The global epidemiology of RSV in community and hospitalized care: findings from 15 countries","volume":"8","author":"Staadegaard","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023050300194358900_dkad076-B61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12879-020-05175-4","article-title":"Global molecular diversity of RSV \u2013 the \u201cINFORM RSV\u201d study","volume":"20","author":"Langedijk","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2023050300194358900_dkad076-B62","doi-asserted-by":"crossref","first-page":"e2284","DOI":"10.1002\/rmv.2284","article-title":"A systematic review on global RSV genetic data: identification of knowledge gaps","volume":"32","author":"Langedijk","year":"2022","journal-title":"Rev Med Virol"},{"key":"2023050300194358900_dkad076-B63","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1586\/eri.11.92","article-title":"Evidence for a causal relationship between respiratory syncytial virus infection and asthma","volume":"9","author":"Wu","year":"2011","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/5\/1143\/50148992\/dkad076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/5\/1143\/50148992\/dkad076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:34:44Z","timestamp":1728992084000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/5\/1143\/7078582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,16]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad076","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,3]]},"published":{"date-parts":[[2023,3,16]]}}}